Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

TakeWhatYouGet Jul. 2 at 5:50 PM

$SCYX noice win and out

0 · Reply

StreakGeek Jul. 2 at 5:16 PM

$TBH $SMX $SCYX $SBFM connecting

0 · Reply

BIG_BEAR_FINANCIAL_LLC Jul. 1 at 3:45 PM

$SLS long bull here and I’m convinced that GPS will meet its endpoints. However I’m a little worried, what happens after ? Let’s say there is no buyout ? After all AML CR2 has a TAM of just a few thousand patients a year, even with a very high cost I can’t see the market being larger than $300 million or so. Right now we are almost at $3 billion so that’s already 10x sales at most (more likely will be 50x sales to start). I can’t see any BP buying us out at this valuation ? Since Sterg doesn’t want to go it alone, but with no buyout, that leaves us to subcontracting the commercialization and marketing. I’ve seen many failed companies with approved once promising drugs fail this route, see $SCYX for instance.

6 · Reply

ViktorSinclair Jun. 30 at 4:27 PM

$SCYX when they acquired the rights to this they said this ALREADY COMPLETED a phase 1 and i think some additional studies as well . why are they doing phase 1 over? how come there was no mention of that within the PR? things like this make David look like a fool. He needs to TALK to the public and take questions.

0 · Reply

LemuelPitkin Jun. 30 at 2:06 PM

$SCYX I am relieved. This is a very short study and now it makes sense.

0 · Reply

LemuelPitkin Jun. 30 at 2:05 PM

$SCYX Grok: Why a new Phase 1 now?Prior development (under Poxel) included several Phase 1 trials plus one Phase 2a in nonalcoholic fatty liver disease (NAFLD), with exposure in ~270+ people and a favorable safety profile. It also had an open IND (for NAFLD) and Orphan Drug Designation for ADPKD. biospace.com +1 This isn't restarting from scratch but conducting a targeted, confirmatory/dose-optimization study under SCYNEXIS's sponsorship for the new indication and development plans. Common reasons for this in biotech acquisitions/transfers include:Dose and regimen optimization for the new indication: ADPKD requires chronic dosing focused on cyst growth reduction via AMPK activation (suppressing mTOR/cAMP pathways).

0 · Reply

LemuelPitkin Jun. 30 at 1:57 PM

$SCYX question: regarding scy-770, did Scynexis ever announce before today that it needed to complete an additional Phase 1 study? AI: No. Before today, Scynexis had not announced that it needed to complete a further phase one safety trial for SCY-770.Instead, when Scynexis acquired the global rights to the drug (formerly known as PXL-770) from Poxel S.A. on March 31, 2026, they noted that the oral therapy had already been evaluated in eight clinical trials with a favorable safety profile. Throughout their spring 2026 corporate updates, they were advancing plans to jump straight into a Phase 2 proof-of-concept study.

0 · Reply

LemuelPitkin Jun. 30 at 1:46 PM

$SCYX did the FDA demand another phase 1 trial for safety? AI Overview +2 SCY-770 is slated to enter a Phase 2 proof-of-concept study for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). This development stage features the following timelines and milestones:Study Initiation: SCYNEXIS, Inc. is scheduled to begin the Phase 2 proof-of-concept trial in the fourth quarter of 2026.Efficacy Readout: Early efficacy data from this study is anticipated in the second half of 2027.Prior Development: SCY-770 (previously known as PXL-770) is a well-characterized oral AMPK activator that has already successfully passed Phase 1 trials and a Phase 2a trial for nonalcoholic fatty liver disease (NAFLD).

0 · Reply

LemuelPitkin Jun. 30 at 1:38 PM

$SCYX isn't scyx-770 supposed to be entering phase 2 studies?

1 · Reply

Windy007 Jun. 30 at 12:52 PM

$SCYX Phase 1! I can hardly contain my excitement!

2 · Reply

Market Cap	43.99M
Revenue (ttm)	20.60M
Net Income (ttm)	-8.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-41.80%
Debt to Equity Ratio	0.00

Volume	222,000
Avg Vol	66,383
Day's Range	N/A - N/A
Shares Out	9.93M
Stochastic %K	71%
Beta	1.11
Analysts	Strong Sell
Price Target	$33.55